Clues to lupus's autoimmune origins in precursor cells

October 10, 2018 by Quinn Eastman, Emory University
Autoreactive CD27 - IgD - CXCR5 - CD11c + (DN2) B cells expand in lupus patients -- DN2 cells derive from naive cells and are poised to generate plasmablasts -- DN2 B cells are hyper-responsive to Toll-like receptor-7 signaling Credit: From Jenks Immunity 2018

In the autoimmune disease systemic lupus erythematosus or SLE, the immune system produces antibodies against parts of the body itself. How cells that produce those antibodies escape the normal "checks and balances" has been unclear, but recent research from Emory University School of Medicine sheds light on a missing link.

Investigators led by Ignacio Sanz, MD, studied blood samples from 90 people living with SLE, focusing on a particular type of B cells. These "DN2" B cells are relatively scarce in healthy people but substantially increased in people with SLE.

People with lupus can experience a variety of symptoms, such as fatigue, joint pain, skin rashes and kidney problems. Levels of the DN2 cells were higher in people with more severe disease or kidney problems. DN2 B cells are thought to be "extra-follicular," which means they are outside the B cell follicles, regions of the lymph nodes where B cells are activated in an immune response.

"Overall, our model is that a lot of lupus auto-antibodies come from a continuous churning out of new responses," says Scott Jenks, Ph.D., co-first author of the paper. "There is good evidence that DN2 cells are part of the early B cell activation pathway happening outside B cells' normal homes in lymph nodes."

Previous research at Emory has shown that African American women have significantly higher rates of lupus than white women. In the current study, the researchers observed that the frequency of DN2 cells was greater in African American patients. Participants in the study were recruited by Emory, University of Rochester and Johns Hopkins.

Sanz, a Georgia Research Alliance Eminent Scholar, is director of the Lowance Center for Human Immunology and head of the division of rheumatology in the Department of Medicine at Emory University School of Medicine. Co-first authors are Jenks, postdoctoral fellow Kevin Cashman, Ph.D. and Esther Zumaquero-Martinez, Ph.D. at the University of Alabama. The lab of Frances Lund, Ph.D. at University of Alabama, as well as postdoc Urko Marigorta, Ph.D. from Georgia Tech contributed to the paper.

The researchers examined the characteristics of DN2 cells and the patterns of genes turned on in those cells. DN2 cells appear to be precursors to the plasmablasts that produce autoreactive antibodies, which cause so much trouble for people with lupus.

Plasmablasts are an important source of antibodies that help get rid of bacteria or viruses during an infection. But in lupus, subsets of B cells and plasmablasts persist in unhealthy ways. In general, we can think of plasmablasts as weapon factories, and B cells as a library of blueprints for various antibodies/weapons. Understanding where the problem plasmablasts come from can provide clues on how to target them and how to control the disease.

Molecular probing showed that DN2 cells in SLE patients are hypersensitive to activation through TLR7, a pathway by which the immune system senses viral infections. This may be how they get over-expanded, Jenks says.

"Our work provides further support for the importance for TLR7 in lupus pathology," he says. "Targeting TLR7 might both block the generation of pathological B cells and prevent their subsequent activation and differentiation into ."

Previous work in Sanz's lab had shown that a group of "activated naïve" B cells are precursors to the problem plasmablasts. Those cells are very similar, in their molecular markers, to DN2 cells. Jenks says the researchers are now figuring out the relationship between DN2 and activated naïve cells, as well as investigating additional intervention strategies that could specifically control those .

Explore further: Researchers decode lupus using DNA clues

More information: Scott A. Jenks et al, Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus, Immunity (2018). DOI: 10.1016/j.immuni.2018.08.015

Related Stories

Researchers decode lupus using DNA clues

November 4, 2015
People with systemic lupus erythematosus can experience a variety of symptoms, such as fatigue, joint pain, skin rashes and kidney problems. Often the symptoms come and go in episodes called flares. In lupus, the immune system ...

Organs are not just bystanders, may be active participants in fighting autoimmune disease

September 24, 2018
Organs affected by autoimmune disease could be fighting back by "exhausting" immune cells that cause damage using methods similar to those used by cancer cells to escape detection, according to a study by researchers at the ...

How antiviral antibodies become part of immune memory

August 15, 2016
Weapons production first, research later. During wartime, governments follow these priorities, and so does the immune system.

Hypertension drugs could prevent memory loss in lupus patients, study suggests

September 5, 2018
Researchers from The Feinstein Institute for Medical Research have discovered that the activation of brain cells called microglia likely contributes to the memory loss and other cognitive impairments suffered by many patients ...

Enzyme keeps antibodies from targeting DNA and driving inflammation in lupus

June 9, 2016
Failure of an enzyme to break down DNA spilling into the bloodstream as cells die may be a major driver of inflammation in lupus. This is the finding of a study in both mice and human patients led by researchers at NYU Langone ...

Subset of plasma cells represent 'historical record' of childhood infections

July 15, 2015
Immunologists from Emory University have identified a distinct set of long-lived antibody-producing cells in the human bone marrow that function as an immune archive.

Recommended for you

A bad influence—the interplay between tumor cells and immune cells

October 16, 2018
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ...

New immunotherapy targeting blood-clotting protein

October 15, 2018
Normally, the blood protein fibrin does not enter the brain. But in several neurological disorders, the blood-brain barrier—which keeps large molecules in the blood from entering the brain—becomes abnormally permeable, ...

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Immune health maintained by meticulously ordered DNA

October 15, 2018
Walter and Eliza Hall Institute researchers have revealed how immune health is maintained by the exquisite organisation skills of a protein called Pax5.

Enzyme that triggers autoimmune responses from T-cells in patients with MS found

October 11, 2018
A team of researchers from Switzerland, the U.S. and Spain has isolated an enzyme that triggers an autoimmune response from T-cells in patients with MS. In their paper published in the journal Science Translational Medicine, ...

Scientists reveal new cystic fibrosis treatments work best in inflamed airways

October 11, 2018
A new UNC School of Medicine study shows that two cystic fibrosis (CF) drugs aimed at correcting the defected CFTR protein seem to be more effective when a patient's airway is inflamed. This is the first study to evaluate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.